Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rawlins, adaptive licensing and EU regulators' fight for fair remuneration*

This article was originally published in SRA

Executive Summary

When Professor Sir Michael Rawlins retired earlier this year after more than a decade as chair of UK health technology assessment body NICE, we suspected we hadn’t seen the last of him. We were right. Sir Michael, who was chair of NICE from its creation in 1999 to April this year, has been appointed to the board of directors of Intra-Cellular Therapies, a US biopharmaceutical company focused on the development of therapeutics for CNS disorders1.

Advertisement
Advertisement
UsernamePublicRestriction

Register

PS117336

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel